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Abstract   
A 28 years’ pregnant woman with 24 weeks’ gestational age referred with petechiae and 
purpura from previous day without any trauma. She had an occipital headache from last 
night. Overt petechial and purpuric lesions were seen in the mouth and skin. There was 
neither hepatosplenomegaly nor lymphadenopathy. She was conscious and oriented. The 
patient was febrile, anemic and thrombocytopenic with stable vital signs. All liver enzymes 
were elevated. Coagulation profile was normal. WBCs were normal. RBCs were reduced, and 
she had polychromatosis. Overt shistocytosis was seen. Platelets were significantly 
decreased. The first diagnosis was TTP. All necessary laboratory tests were done to rule out 
the secondary rheumatologic causes of TTP; which all were normal. Coombs tests were 
negative. ADAMTS 13 Ab was elevated. Fetal ultrasonography was normal. 
Treatment started with plasmapheresis and corticosteroid. After treatment, platelets count 
begins elevated, and LDH decreased. The patient discharged with a good general condition 
and normal lab tests. She continued her pregnancy until term, and born a normal infant 
without any complication. She did not have a recurrence of TTP until September 2014.  
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 Introduction
Thrombotic thrombocytopenic purpura 
(TTP) is a rare, acute, and life-threatening 
disease (1). TTP is a multiple organ 
disorder characterized by 
microangiopathic hemolytic anemia, 
thrombocytopenia, neurological symptoms 
and renal involvement (2, 3) caused from 
ADAMTS13 deficiency (1). 
The presentation age of acute TTP is the 
third and fourth decades. Fifty percent of 
all acute episodes of TTP are in women of 
childbearing age (1, 4). 
Pregnancy is one of the most important 
precipitating events for acute episodes of 
TTP. The reasons are an association of 
pregnancy with increasing of procoagulant 
factors, decreasing fibrinolytic activity, 
loss of endothelial cell thrombomodulin 
and decreasing the activity of ADAMTS13 
(2, 3). ADAMTS13 is a protease enzyme 
that involved in the cleavage of Von 
Willebrand factor. All of these 
abnormalities become progressively severe 
in the late stages pregnancy (1-3). 
Case report  
A 28-year-old woman with 24 weeks’ 
gestational age pregnancy referred to Al-
Zahra hospital, Isfahan, Iran at September 
2013 with whole body petechiae and 
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purpura from previous day without any 
trauma. She had an occipital headache 
from last night. 
In history, she did not have a headache or 
purpura. She did a laparoscopic surgery for 
ovarian cystectomy without complication 
last year. 
In physical examination, overt petechial 
and purpuric lesions were seen in the 
mucosa of mouth and skin especially in 
lower extremities. There was neither 
hepatosplenomegaly nor 
lymphadenopathy. She was conscious and 
oriented. Previous laboratory data in 
pregnancy was normal. The patient was 
febrile (T=37.7), anemic (Hb=8.6) and 
thrombocytopenic (Plt=4000) with stable 
vital signs. All liver enzymes (Bil=1.5, 
AST=62, ALT=42, ALP=183, 
LDH=1630) were elevated. Coagulation 
profile was normal. In urine analysis, 
hematuria was seen. ESR was elevated 
(100). Creatinine was normal. In 
peripheral blood smear, WBCs was 
normal. RBCs were reduced, and she had 
polychromatosis. Overt shistocytosis 
(more than %10) were seen. Platelets were 
significantly decreased also. 
With these findings, the first diagnosis was 
TTP (thrombotic thrombocytopenic 
purpura). HELLP (hemolysis, elevated 
liver enzymes, and low platelets) 
syndrome was in the differential diagnosis. 
Lupus anticoagulant antibody (LAC ab), 
anti-thrombin III, anti-cardiolipin antibody 
(AC ab), ANA, Anti-ds DNA, ANCA, 
Anti b2Gp1, C3, C4, and CH50 were done 
to rule out the secondary rheumatologic 
causes of TTP; which all were normal. 
Direct and indirect Coombs tests were 
negative. ADAMTS 13 Ab (288) was 
elevated. The fetal ultrasonography was 
normal. 
Treatment started with plasmapheresis (2.5 
lit/day) with FFP replacement, and 
corticosteroid (prednisolone 20 mg/TDS). 
Before plasmapheresis, she received 
packed cell and calcium gluconate. After 
three days from beginning of treatment, 
platelets counts begin elevated, and LDH 
decreased. Plasmapheresis continued for 
two days later, then one other day for three 
times. Prednisolone tapered and 
interrupted also. The patient discharged 
with folic acid and ASA (80 mg/day) and 
followed with CBC count and LDH every 
two weeks with a good general condition. 
Laboratory data became normal (Hb=11.8, 
Plt=202000, LDH=289) . 
She continued her pregnancy until term 
(38 weeks). She did NVD and born a well 
male infant with 3100 gr weight without 
any complication. She did not have a 
recurrence of TTP until September 2014. 
A few cases of TTP in pregnancy were 
recovered from this disease, so we report 
this successful treatment as a case report. 
Discussion 
The major of TTP cases occur at time of 
delivery or immediately postpartum. It is 
associated with a considerable risk to 
maternal and fetus without treatment. 
Diagnosis of this problem is too hard 
during pregnancy because the symptoms 
mimic of preeclampsia, HELLP, eclampsia 
or any other coagulopathy. Fetal death is 
occurred secondary to placental infarction, 
and maternal death occurs from 
thrombocytopenia, acute renal failure, or 
disseminated intravascular coagulation 
(DIC) (1, 5).  
Plasma exchange is the main treatment for 
TTP. When this disease occurs in the late 
of pregnancy, and the fetus has gained 
enough maturity, pregnancy could be 
terminated for an aggressive treatment. 
But when it occurs early in pregnancy as 
in our case, therapeutic abortion is 
considered by many clinicians, because the 
risk of repeated TTP episodes is very high. 
With using of plasma exchange could 
maintain a remission of TTP and a full 
term delivery. However, if plasma 
exchange fails to induce remission, a 
therapeutic abortion could be considered. 
The response of TTP to terminate the 
pregnancy is unknown. Although we had a 
successful treatment with this patient and 
her pregnancy outcome, there was always 
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risk of future episodes of TTP. Based on 
the British Committee for Standards in 
Hematology guidelines, plasma exchange 
should be used in pregnant women with 
TTP disorder as for non-pregnant patients 
(6).  
Delivery is administrated only for TTP 
patients who do not have response to 
treatment with therapeutic plasma 
exchange (TPE).  Plasma exchange must 
be continued even after platelet count 
normalization, and resolution of hemolysis 
must be documented. McMinn et al. have 
showed that the plasma volume increases 
in pregnancy does not affect the response 
of TTP to TPE, and TPE does not affect 
the outcome of pregnancy (7, 8). 
ADAMTS13 deficiency is not a general 
finding; and its measurement is not 
recommended commonly for diagnoses of 
TTP. TTP may respond to TPE even in the 
ADAMTS13 deficiency. Intravenous 
immunoglobulins (IVIG) and 
glucocorticoids like methylprednisolone 
and oral prednisolone could be used in the 
treatment of TTP also. 
The risk of TTP recurrence in subsequent 
pregnancies will remain an important 
problem. We advise that if these women 
managed by a unit of obstetricians, 
hematologists, and nephrologists in 
hospitals where TPE is available a 
successful treatment and a good outcome 
could be expected. 
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